Correlation Between Body Mass Index and Immunotherapy Response in Advanced NSCLC.

BACKGROUND

Immune checkpoint inhibitors (ICIs) have revolutionized the management of advanced non-small cell lung cancer (NSCLC). Emerging evidence suggests a potential association between elevated body mass index (BMI) and enhanced ICI efficacy, yet this relationship remains inconclusive and warrants further investigation. This study aims to evaluate the impact of BMI on treatment efficacy and survival outcomes in advanced NSCLC patients treated with first-line ICI therapy.

METHODS

A retrospective study was conducted at a multi-center registry to evaluate the impact of baseline BMI on overall survival (OS) and progression-free survival (PFS) in patients with stage IV NSCLC who received first-line ICI therapies. Treatment regimens included pembrolizumab or the combination of ipilimumab and nivolumab, administered either as monotherapy or in combination with chemotherapy, at the oncology department between January 2018 and December 2023. BMI was categorized according to the World Health Organization (WHO) classification, and OS and PFS were evaluated using Kaplan-Meier survival analysis and the Cox proportional hazards regression model.

RESULTS

Among 346 patients, 12.72% were underweight, 45.38% normal weight, 29.19% overweight, and 12.72% obese. Overweight and obese patients were more likely to receive pembrolizumab ( = 0.039) and less likely to undergo chemotherapy ( = 0.012). No significant differences in median overall survival (OS, log-rank: = 0.155) or progression-free survival (PFS, log-rank: = 0.370) were observed across BMI categories. However, differences emerged upon further analysis of PD-L1 levels (OS, log-rank: = 0.029; PFS, log-rank: = 0.044), additional chemotherapy (OS, log-rank: = 0.009; PFS, log-rank: = 0.021), type of immune checkpoint inhibitor (OS, log-rank: < 0.001; PFS, log-rank: < 0.001), and histologic diagnosis (OS, log-rank: = 0.011; PFS, log-rank: = 0.003).

CONCLUSIONS

BMI was not an independent predictor of survival outcomes in advanced NSCLC treated with ICI. Incorporating BMI with other patient-specific factors into personalized immunotherapy strategies highlights the importance of tailored approaches to improve patient care and clinical outcomes.